A Phase Ib-II Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. A Study of the Dutch Head and Neck Society
Phase of Trial: Phase I/II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Cetuximab (Primary) ; Methotrexate
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms COMMENCE
- 31 May 2017 Planned number of patients changed from 120 to 51.
- 31 May 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
- 31 May 2017 Status changed from suspended to recruiting.